We found that USH2A mutant tumors have stronger immunogenicity, exhibited as higher TMB, increased immune cell infiltration into tumor tissues, and overexpression of immune checkpoint factors such as PD1, PDL1, and CTLA4. This indicates that the USH2A mutation can enhance tumor immunogenicity, allowing tumor patients to benefit from antitumor immunotherapy. The gene discussed is CTLA4; the disease is neoplasm.